Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Pyoderma Gangrenosum
NCT02733094Phase 2Completed
- Sponsor
- Technical University of Munich
- Start
- Apr 2016
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of secukinumab in pyoderma gangrenosum (PG), sponsored by Technical University of Munich. Started Apr 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT02733094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02733094.